Type-A patients who were already being treated by anti-thrombotic drugs were significantly older, and showed a higher prevalence of previous history of atrial fibrillation, cardiovascular disease, coronary artery bypass graft, and aortic valve replacement, as well as increased use of renin-angiotensin-aldosterone system (RAAS) inhibitors (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers), calcium channel blockers, and β-blockers. This evidence concerns the gene ACE and atrial fibrillation.